Is Our Investment Getting Us the Health Results We're Paying For?
This article was originally published in RPM Report
Pfizer CEO Jeff Kindler sees theenvironment for pharma continuing to evolve at a fast pace. In a broad, direct speech to the leading PBM trade group he notes that pharm companiesare habving to adapt to a new world in which they do not exclusively control the information about their products. The changes will force pharm to pursue new opportunites, such as product differentiation through clinical services.
You may also be interested in...
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.